Blood filtration company ExThera Medical Corporation announced on Tuesday that physicians are using its Seraph 100 Microbind Affinity Blood Filter (Seraph 100) under the US Food and Drug Administration's emergency use authorisation to treat critically ill COVID patients.
Under the first multicentre randomized controlled trial of the Seraph 100, the company said it successfully treated hundreds of COVID patients and will be studying the treatment's ability to reduce ICU length of stay, hospital duration and mortality in patients suffering from septic shock.
With scheduled enrollment this Fall, the study will evaluate the safety and efficacy of pathogen-removing extracorporeal blood purification therapy in critically ill patients with pathogen-associated shock utilizing the company's Seraph 100 filter. The study will serve as the investigational device exemption (IDE) research needed for Seraph 100's FDA clearance.
This trial is sponsored by the Henry M. Jackson Foundation for the Advancement of Military Medicine in collaboration with the Uniformed Services University (USU) of the Health Sciences.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project